[Treatment of cerebral vascular diseases due to softening].
D000368:Aged; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002110:Caffeine / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004678:Encephalomalacia / Q000188:drug therapy*; D004877:Ergoloid Mesylates / Q000627:therapeutic use*; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009705:Nucleosides / Q000627:therapeutic use*; D010208:Papaverine / Q000627:therapeutic use*; D011343:Procaine / Q000627:therapeutic use*
D005419:Flavonoids; D009705:Nucleosides; D002110:Caffeine; D011343:Procaine; D004877:Ergoloid Mesylates; D010208:Papaverine; D001205:Ascorbic Acid
Sulla terapia delle lesioni vascolari cerebrali da rammollimento.